Vapaliximab

Vapaliximab is an experimental drug currently under development for the treatment of various cancer types. It is a monoclonal antibody that targets the glycoprotein CD47, a protein often overexpressed on the surface of cancer cells.

Mechanism of Action

Vapaliximab works by binding to CD47, a protein that is often overexpressed on the surface of cancer cells. CD47 acts as a "don't eat me" signal, preventing the body's immune system from attacking the cancer cells. By binding to CD47, Vapaliximab blocks this signal, allowing the immune system to recognize and destroy the cancer cells.

Clinical Trials

Vapaliximab is currently in clinical trials for the treatment of various types of cancer. These trials aim to determine the safety, efficacy, and optimal dosage of the drug.

Potential Applications

If successful in clinical trials, Vapaliximab could be used to treat a wide range of cancers, including leukemia, lymphoma, and solid tumors.

See Also

• Monoclonal antibodies in cancer therapy
• CD47
• Clinical trials

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian